Glenmark Pharmaceuticals Update by Epic Research

Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals (GPL) has entered into Oncology with the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody.



Real Time News & Trading Trends Keep Liking #EpicResearch




Facebook – Twitter – YouTube – Pinterest –Linkedin - Google+



For more information ✆ – 0731-6642300 or Visit http://ift.tt/1k8NnLH

Posted in: Indian Market Tips